Literature DB >> 26140959

Protein sequence conservation and stable molecular evolution reveals influenza virus nucleoprotein as a universal druggable target.

Mustafeez Mujtaba Babar1, Najam-us-Sahar Sadaf Zaidi2.   

Abstract

The high mutation rate in influenza virus genome and appearance of drug resistance calls for a constant effort to identify alternate drug targets and develop new antiviral strategies. The internal proteins of the virus can be exploited as a potential target for therapeutic interventions. Among these, the nucleoprotein (NP) is the most abundant protein that provides structural and functional support to the viral replication machinery. The current study aims at analysis of protein sequence polymorphism patterns, degree of molecular evolution and sequence conservation as a function of potential druggability of nucleoprotein. We analyzed a universal set of amino acid sequences, (n=22,000) and, in order to identify and correlate the functionally conserved, druggable regions across different parameters, classified them on the basis of host organism, strain type and continental region of sample isolation. The results indicated that around 95% of the sequence length was conserved, with at least 7 regions conserved across the protein among various classes. Moreover, the highly variable regions, though very limited in number, were found to be positively selected indicating, thereby, the high degree of protein stability against various hosts and spatio-temporal references. Furthermore, on mapping the conserved regions on the protein, 7 drug binding pockets in the functionally important regions of the protein were revealed. The results, therefore, collectively indicate that nucleoprotein is a highly conserved and stable viral protein that can potentially be exploited for development of broadly effective antiviral strategies.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Drug target; Influenza; Molecular evolution; Nucleoprotein; Sequence conservation

Mesh:

Substances:

Year:  2015        PMID: 26140959     DOI: 10.1016/j.meegid.2015.06.030

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  8 in total

1.  Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein.

Authors:  Kris M White; Pablo Abreu; Hui Wang; Paul D De Jesus; Balaji Manicassamy; Adolfo García-Sastre; Sumit K Chanda; Robert J DeVita; Megan L Shaw
Journal:  ACS Infect Dis       Date:  2018-01-04       Impact factor: 5.084

2.  Interactions between Influenza A Virus Nucleoprotein and Gene Segment Untranslated Regions Facilitate Selective Modulation of Viral Gene Expression.

Authors:  Meghan Diefenbacher; Timothy J C Tan; David L V Bauer; Beth M Stadtmueller; Nicholas C Wu; Christopher B Brooke
Journal:  J Virol       Date:  2022-04-25       Impact factor: 6.549

3.  Influenza Virus Vaccination Elicits Poorly Adapted B Cell Responses in Elderly Individuals.

Authors:  Carole Henry; Nai-Ying Zheng; Min Huang; Alexandra Cabanov; Karla Thatcher Rojas; Kaval Kaur; Sarah F Andrews; Anna-Karin E Palm; Yao-Qing Chen; Yang Li; Katerina Hoskova; Henry A Utset; Marcos C Vieira; Jens Wrammert; Rafi Ahmed; Jeanne Holden-Wiltse; David J Topham; John J Treanor; Hildegund C Ertl; Kenneth E Schmader; Sarah Cobey; Florian Krammer; Scott E Hensley; Harry Greenberg; Xiao-Song He; Patrick C Wilson
Journal:  Cell Host Microbe       Date:  2019-02-19       Impact factor: 21.023

4.  Identification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches.

Authors:  Juliann Nzembi Makau; Ken Watanabe; Takeshi Ishikawa; Satoshi Mizuta; Tsuyoshi Hamada; Nobuyuki Kobayashi; Noriyuki Nishida
Journal:  PLoS One       Date:  2017-03-08       Impact factor: 3.240

5.  Randomized, Double-Blind, Reference-Controlled, Phase 2a Study Evaluating the Immunogenicity and Safety of OVX836, A Nucleoprotein-Based Influenza Vaccine.

Authors:  Isabel Leroux-Roels; Gwenn Waerlop; Jessika Tourneur; Fien De Boever; Catherine Maes; Jacques Bruhwyler; Delphine Guyon-Gellin; Philippe Moris; Judith Del Campo; Paul Willems; Geert Leroux-Roels; Alexandre Le Vert; Florence Nicolas
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

6.  Phase 1 Randomized, Placebo-Controlled, Dose-Escalating Study to Evaluate OVX836, a Nucleoprotein-Based Influenza Vaccine: Intramuscular Results.

Authors:  Kanchanamala Withanage; Ilse De Coster; Nathalie Cools; Simonetta Viviani; Jessika Tourneur; Marion Chevandier; Manon Lambiel; Paul Willems; Alexandre Le Vert; Florence Nicolas; Pierre Van Damme
Journal:  J Infect Dis       Date:  2022-08-12       Impact factor: 7.759

Review 7.  The role of cell-mediated immunity against influenza and its implications for vaccine evaluation.

Authors:  Yorick Janssens; Jasper Joye; Gwenn Waerlop; Frédéric Clement; Geert Leroux-Roels; Isabel Leroux-Roels
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

8.  OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.

Authors:  Andres Pizzorno; Sophia Djebali; Judith Del Campo; Julien Bouley; Marjorie Haller; Jimena Pérez-Vargas; Bruno Lina; Guy Boivin; Marie-Eve Hamelin; Florence Nicolas; Alexandre Le Vert; Yann Leverrier; Manuel Rosa-Calatrava; Jacqueline Marvel; Fergal Hill
Journal:  NPJ Vaccines       Date:  2019-01-23       Impact factor: 7.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.